NSEI:JBCHEPHARM

Stock Analysis Report

J. B. Chemicals & Pharmaceuticals

Executive Summary

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and APIs in India and internationally.

Snowflake

Fundamentals

Flawless balance sheet with solid track record and pays a dividend.

Share Price & News

How has J. B. Chemicals & Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.4%

NSEI:JBCHEPHARM

-0.2%

IN Pharmaceuticals

-2.1%

IN Market


1 Year Return

13.6%

NSEI:JBCHEPHARM

-24.2%

IN Pharmaceuticals

-14.7%

IN Market

JBCHEPHARM outperformed the Pharmaceuticals industry which returned -24.1% over the past year.

JBCHEPHARM outperformed the Market in India which returned -14.6% over the past year.


Share holder returns

JBCHEPHARMIndustryMarket
7 Day-0.4%-0.2%-2.1%
30 Day0.6%-2.8%-3.9%
90 Day-0.5%-6.9%-10.1%
1 Year15.8%13.6%-23.5%-24.2%-12.9%-14.7%
3 Year13.8%11.2%-24.3%-25.9%17.7%11.5%
5 Year97.8%78.0%-6.8%-9.7%35.4%22.5%

Price Volatility Vs. Market

How volatile is J. B. Chemicals & Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is J. B. Chemicals & Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

14.51x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

J. B. Chemicals & Pharmaceuticals's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

J. B. Chemicals & Pharmaceuticals's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

J. B. Chemicals & Pharmaceuticals is good value based on earnings compared to the IN Pharmaceuticals industry average.

J. B. Chemicals & Pharmaceuticals is overvalued based on earnings compared to the India market.


Price Based on Expected Growth

J. B. Chemicals & Pharmaceuticals is poor value based on expected growth next year.


Price Based on Value of Assets

J. B. Chemicals & Pharmaceuticals is overvalued based on assets compared to the IN Pharmaceuticals industry average.


Next Steps

Future Growth

How is J. B. Chemicals & Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

12.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

J. B. Chemicals & Pharmaceuticals's revenue is expected to grow by 9.4% yearly, however this is not considered high growth (20% yearly).

J. B. Chemicals & Pharmaceuticals's earnings are expected to grow by 12.4% yearly, however this is not considered high growth (20% yearly).

J. B. Chemicals & Pharmaceuticals's revenue growth is positive but not above the India market average.

J. B. Chemicals & Pharmaceuticals's earnings growth is positive but not above the India market average.

J. B. Chemicals & Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 7.6%.


Earnings per Share Growth Estimates


Future Return on Equity

J. B. Chemicals & Pharmaceuticals is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has J. B. Chemicals & Pharmaceuticals performed over the past 5 years?

11.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

J. B. Chemicals & Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years.

J. B. Chemicals & Pharmaceuticals's 1-year earnings growth exceeds its 5-year average (38% vs 11.2%)

J. B. Chemicals & Pharmaceuticals's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (38% vs 15.4%).


Return on Equity

J. B. Chemicals & Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

J. B. Chemicals & Pharmaceuticals used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

J. B. Chemicals & Pharmaceuticals has improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is J. B. Chemicals & Pharmaceuticals's financial position?


Financial Position Analysis

J. B. Chemicals & Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

J. B. Chemicals & Pharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

J. B. Chemicals & Pharmaceuticals's level of debt (1.7%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (9.9% vs 1.7% today).

Debt is well covered by operating cash flow (748.4%, greater than 20% of total debt).

J. B. Chemicals & Pharmaceuticals earns more interest than it pays, coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 40.7x debt.


Next Steps

Dividend

What is J. B. Chemicals & Pharmaceuticals's current dividend yield, its reliability and sustainability?

1.32%

Expected Dividend Yield


Dividend Yield and Payments Analysis

J. B. Chemicals & Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.65%).

J. B. Chemicals & Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (2.64%).

Dividends per share have been volatile in the past 10 years (annual drop of over 20%).

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are well covered by earnings (5.2x coverage).


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (5.3x coverage).


Next Steps

Management

What is the CEO of J. B. Chemicals & Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

₹64m

CEO Compensation


CEO

Jyotindra Mody (90yo)

0.0yrs

Tenure

₹64,076,000

Compensation

Mr. Jyotindra Bhagwanlal Mody serves as Chairman and Managing Director at J. B. Chemicals & Pharmaceuticals Ltd. Mr. Mody has experience of over four decades in the Indian pharmaceutical industry. Mr. Mody ...


CEO Compensation Analysis

Jyotindra's remuneration is higher than average for companies of similar size in India.

Jyotindra's compensation has been consistent with company performance over the past year, both up more than 20%.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

Sell₹9,629,46122 Feb 19
Nitin Doshi
EntityIndividual
Shares30,186
Max Price₹319.00

Ownership Breakdown


Management Team

  • Kamlesh Udani (65yo)

    Director of Technical & Production and Executive Director

    • Tenure: 0.0yrs
    • Compensation: ₹18.18m
  • Sandeep Nasa

    Head of Moscow Representative Office - Marketing & Head of Russia - CIS Business

    • Tenure: 0.0yrs
    • Compensation: ₹23.64m
  • Shirish Mody (78yo)

    Director of Marketing & Whole-Time Director

    • Tenure: 0.0yrs
    • Compensation: ₹64.08m
  • Pranabh Mody (56yo)

    President

    • Tenure: 0.0yrs
    • Compensation: ₹28.11m
  • Jyotindra Mody (90yo)

    Chairman & MD

    • Tenure: 0.0yrs
    • Compensation: ₹64.08m
  • Dinesh Mody (83yo)

    Director of Administration & Whole-Time Director

    • Tenure: 0.0yrs
    • Compensation: ₹64.08m
  • Bharat Sukhlal Mehta (71yo)

    Director of Planning & Development and Whole-Time Director

    • Tenure: 0.0yrs
    • Compensation: ₹28.11m
  • Pradeep Singh (55yo)

    President of Global Business

    • Tenure: 0.0yrs
  • Mayur Mehta

    Company Secretary & VP of Compliance

    • Tenure: 0.0yrs
  • Vijay Bhatt

    Chief Financial Officer

    • Tenure: 0.0yrs

Board Members

  • Shad Mapetla (68yo)

    Chairman of Biotech Laboratories (Pty ) Ltd

    • Tenure: 0.0yrs
  • Kamlesh Udani (65yo)

    Director of Technical & Production and Executive Director

    • Tenure: 0.0yrs
    • Compensation: ₹18.18m
  • Shirish Mody (78yo)

    Director of Marketing & Whole-Time Director

    • Tenure: 0.0yrs
    • Compensation: ₹64.08m
  • Pranabh Mody (56yo)

    President

    • Tenure: 0.0yrs
    • Compensation: ₹28.11m
  • Jyotindra Mody (90yo)

    Chairman & MD

    • Tenure: 0.0yrs
    • Compensation: ₹64.08m
  • Dinesh Mody (83yo)

    Director of Administration & Whole-Time Director

    • Tenure: 0.0yrs
    • Compensation: ₹64.08m
  • Bharat Sukhlal Mehta (71yo)

    Director of Planning & Development and Whole-Time Director

    • Tenure: 0.0yrs
    • Compensation: ₹28.11m
  • Durga Chopra (86yo)

    Non Executive Independent Director

    • Tenure: 12.3yrs
    • Compensation: ₹860.00k
  • Satyanarain Agarwala

    Independent Director

    • Tenure: 9.1yrs
    • Compensation: ₹980.00k
  • Krupa Gandhi

    Independent Director

    • Tenure: 0.0yrs
    • Compensation: ₹900.00k

Company Information

J. B. Chemicals & Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: J. B. Chemicals & Pharmaceuticals Limited
  • Ticker: JBCHEPHARM
  • Exchange: NSEI
  • Founded: 1976
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹30.025b
  • Shares outstanding: 80.24m
  • Website: https://www.jbcpl.com

Location

  • J. B. Chemicals & Pharmaceuticals Limited
  • Cnergy IT Park
  • Unit A2, 3rd floor & Unit A, 8th floor
  • Mumbai
  • Maharashtra
  • 400030
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
506943BSE (Mumbai Stock Exchange)YesEquity SharesININRDec 2001
JBCHEPHARMNSEI (National Stock Exchange of India)YesEquity SharesININRDec 2001

Biography

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets various pharmaceutical formulations, herbal remedies, and APIs in India and internationally. The company manufactures a range of specialty ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/24 12:46
End of Day Share Price2019/08/23 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.